All Jeanne Marrazzo articles
-
NewsLong-acting injectable cabotegravir for HIV prevention is safe in pregnancy
Long-acting injectable cabotegravir (CAB-LA) was safe and well tolerated as HIV pre-exposure prophylaxis (PrEP) before and during pregnancy in the follow-up phase of a global study.
-
NewsIsolated viral load test may generate false positive results for people using long-acting PrEP
A single laboratory-based HIV viral load test used by U.S. clinicians who provide people with long-acting, injectable cabotegravir (CAB-LA) HIV pre-exposure prophylaxis (PrEP) did not reliably detect HIV in a multi-country study.
-
NewsExperimental NIH malaria monoclonal antibody protective in Malian children
One injected dose of an experimental malaria monoclonal antibody was 77% effective against malaria disease in children in Mali during the country’s six-month malaria season, according to the results of a mid-stage clinical trial.
-
NewsLong-acting HIV treatment benefits adults with barriers to daily pill taking and adolescents with suppressed HIV
Long-acting, injectable antiretroviral therapy (ART) suppressed HIV replication better than oral ART in people who had previously experienced challenges taking daily oral regimens and was found safe in adolescents with HIV viral suppression.
-
NewsChildren surpass a year of HIV remission after treatment pause
Four children have remained free of detectable HIV for more than one year after their antiretroviral therapy (ART) was paused to see if they could achieve HIV remission.
